CA-DENODO
9.6.2022 09:02:06 CEST | Business Wire | Press release
Denodo , a leader in data management, today released the findings of its sixth annual cloud usage survey which revealed that cloud adoption is continuing its rapid climb, with more than half (54%) of participants stating they are either at an intermediate or advanced level of cloud usage. Cloud-enabled business transformation has become a priority as organizations face global supply chain issues, cybersecurity threats, and geopolitical instability. While organizations of all sizes and vertical markets are turning to the cloud to ensure flexibility and resilience in the face of these challenges, small to medium sized businesses have driven investment in cloud infrastructure services to support workload migration, data storage services, and cloud-native application development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607006385/en/
Download the complimentary findings here .
Cloud-based data warehouses, data lakes, and lake houses played a prominent role in 2021, and was cited as both a top initiative by respondents (48%) and a top use case (57%). Hybrid cloud continues to be the deployment model of choice as it has been since the 2020 survey. However, this year, the gap between hybrid cloud and private cloud is dramatically wider. Hybrid cloud was chosen by almost twice the number of respondents (37.5%), compared with pure public cloud, at 20%. This year, it is clear that hybrid cloud is less a “choice” but a “necessity” and indicates that companies are not completely getting rid of their on-premises systems even if they have increased their cloud footprint. Companies have good reasons for deploying this mixed deployment style, regulatory compliance among them, which may be why they are opting not to simply abandon on-premises systems when the technology landscape changes.
As it relates to these survey respondent companies being data-driven, nearly four in five respondents (79%) cited complexity of data integration, data accessibility, and accommodating different data formats as the primary barrier to becoming data-driven followed by the lack of analytical skills and resources to turn raw data into insights (62%). Data scientists struggled as well. Often cited for spending more time finding, accessing, and preparing data than they do analyzing it, more than 2 out of five (44%) were unable to find, access, and analyze half or more of their data after adopting cloud technologies and only 17% were able to leverage 75% or more of their data.
The role of IT in the cloud modernization journey has also changed. In 2020, the focus for tech professionals was choosing the appropriate cloud provider and managing the migration. But in 2021, these IT teams are more focused on receiving the training needed to take their organization’s cloud systems to the next level (as per 31.3% of survey respondents), while other activities such as selecting cloud provider and planning for cloud migrations still remain important. Companies are using cloud for various use cases with the most popular being reporting and dashboards, and self-service BI and ad-hoc analytics; however, respondents anticipate a shift to data virtualization, data preparation, data quality and blending in the future.
These use cases paint a vivid portrait of where many organizations are with respect to their cloud journeys. First, it reflects the fact that the business stakeholders within organizations are ready to get better use out of their data, and second, it shows that organizations are now looking to maximize their cloud systems with robust cloud-based repositories. Having migrated key workloads to the cloud, the next step for many companies is to find a place to store the new data they then begin to acquire. Modern data-management approaches like logical data fabric enable organizations to seamlessly accommodate legacy systems so that they can work in tandem with cloud systems.
“Audiences continue to express their need for real-time data so it is no surprise that availability, with regard to data integration, management, and analytics in the cloud, is not only ‘nice to have,’ but critical to becoming data-driven,” said Ravi Shankar, senior vice president and chief marketing officer of Denodo. “This is true across all configurations, but the reality is most organizations are unable to find, access, and analyze half or more of their data after adopting cloud technologies. That may be why the overwhelming majority of organizations (93%) stated that they were using, evaluating, or considering leveraging cloud-based data integration, management, and analytics including powerful technologies, such as data virtualization and logical data fabric to provide seamless, real-time access across both on-premises and cloud systems.”
When it comes to choosing cloud service providers, Microsoft Azure and Amazon Web Services (AWS) continue to dominate the market by a wide margin, but this year, AWS (44.6%) has jumped ahead of Azure (26.2%) with a substantial lead, after Azure has kept just ahead of AWS for two consecutive years. Google Cloud Platform (GCP) came in as a third most popular option (8%), according to the survey. In contrast, Alibaba showed a bump from 1.4% in 2021 to 3.6% this year.
Methodology:
The Denodo Global Cloud Survey 2022 surveyed stakeholders at over 150 organizations across 3 major global regions – North America, EMEA, and APAC – to understand where organizations are in their cloud adoption journeys. Surveys were fielded online to data and cloud professionals from various backgrounds and roles in March of 2022. The results from the Denodo Global Cloud Survey 2022 are available for download here .
Please Tweet: https://bit.ly/3Nt7uZ1
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053 / +65 6950 7489.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006385/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
